

Table of Contents

Abbreviations and Acronyms.....	11
Preface	14
Executive Summary	15
<i>Chapter 1. Defining the Bioeconomy</i>	19
What is a bioeconomy?	22
Foreseeing the emerging bioeconomy.....	26
Notes	28
References.....	29
<i>Chapter 2. What External Factors Will Drive the Bioeconomy to 2030?</i>	31
Population and income	33
Demographics and human resources.....	37
Energy consumption and climate change.....	38
Agriculture, food prices and water	40
Healthcare costs	41
Supporting and competing technologies	42
Summary of drivers.....	44
Notes	47
References.....	48
<i>Chapter 3. The State of the Bioeconomy Today</i>	51
Platform technologies.....	52
Biotechnology applications in primary production	55
Biotech applications in health	63
Biotech applications in industry	72
Biofuels	79
The bioeconomy today	85

Notes	86
Annex 3.A1. USDA-Approved GM Varieties	89
Annex 3.A2. <i>Haute Autorité de Santé</i> (HAS) Therapeutic Value Classifications	90
Annex 3.A3. Analysis of <i>Prescrire</i> Therapeutic Value Evaluations	91
References.....	92
<i>Chapter 4. The Bioeconomy to 2015</i>	99
Platform technologies to 2015.....	100
Biotech applications to 2015 in primary production	103
Biotech applications to 2015 in human health	109
Biotech applications to 2015 in industry	119
Biofuels to 2015	124
The bioeconomy in 2015.....	129
Notes	130
References.....	132
<i>Chapter 5. Institutional and Social Drivers of the Bioeconomy</i>	137
Public research	138
Regulation	144
Intellectual property rights	152
Social attitudes	153
Notes	156
References.....	158
<i>Chapter 6. The Business of the Emerging Bioeconomy</i>	163
Current business models for biotechnology	164
Emerging business models in biotechnology	171
Conclusions.....	184
Notes	185
Annex 6.A1. R&D Expenditures by Leading Firms Active in Biotechnology	188
References.....	189

<i>Chapter 7. The Bioeconomy of 2030</i>	193
Introduction	194
The probable bioeconomy in 2030.....	194
Scenarios for the bioeconomy of 2030.....	202
Conclusions.....	209
Notes.....	210
Annex 7.A1. Fictional Scenarios to 2030	211
References.....	232
<i>Chapter 8. Policy Options for the Bioeconomy: The Way Ahead</i>	235
Primary production.....	241
Health applications.....	248
Industrial applications	258
Cross-cutting issues.....	266
The global challenge	269
Timing.....	272
The complex policy context	274
Notes.....	275
References.....	279
<i>Chapter 9. Conclusions: On the Road to the Bioeconomy</i>	285
Main findings	287
Concluding comments.....	293
Notes.....	294
<i>Annex A. Members of the Bioeconomy to 2030 Steering Group</i>	295
<i>Annex B. External Experts Involved in the Bioeconomy to 2030 Project</i>	302
<i>Glossary of Selected Scientific and Technical Terms</i>	307

List of tables

2.1. Population and per capita GDP in 2005 and 2030, by region.....	34
2.2. Population living in areas under water stress	41
2.3. Drivers for the bioeconomy	45
3.1. HAS evaluations of the therapeutic value of biopharmaceuticals and all other drugs	66
3.2. Valid FDA genomic biomarkers and genetic testing requirements, September 2008	70
3.3. Examples of biopolymer production facilities in use or development	74
3.4. Characteristics of new types of biorefineries	79
3.5. Percentage of all field trials in select food crops involving potential biofuel traits, 1987-2006.....	81
3.6. An overview of some current biofuel production technologies and research goals	84
3.A1.1. USDA-approved and pending GM crop varieties as of 1 May 2007.....	89
3.A3.1. <i>Prescribe</i> evaluations of the therapeutic value of biopharmaceuticals and all other drugs (January 1986–December 2007)	91
3.A3.2. Definition of <i>Prescribe</i> evaluation categories.....	91
4.1. The current status and prospects to 2015 of some important platform technologies	102
4.2. The current status and prospects to 2015 of some important biotechnology applications in primary production	108
4.3. Share of all biotechnology clinical trials in proven and experimental biotherapies, by phase.....	113
4.4. The current status and prospects to 2015 of some important biotechnology applications in health	118
4.5. Bio-based chemical R&D: US survey respondents' expenditures and employment, 2004-07	120
4.6. Projected value of world chemical production: 2005, 2010 and 2025	121
4.7. The current status and prospects to 2015 of some important biotechnology applications in industry	127
5.1. Indicative regulatory costs to commercialise a biotechnology product.....	146
6.1. Percentage of all GM field trials by the leading firms.....	168
6.2. Concentration of R&D in pharmaceuticals and health biotechnology	170
6.A1.1. Estimated 2006 R&D expenditures of relevance to biotechnology by leading companies in each application	188
7.1. Biotechnologies with a high probability of reaching the market by 2030.....	195
7.2. Maximum potential contribution of biotechnology to gross value added and employment.....	200
7.3. Current R&D expenditures versus future markets for biotechnology by application	201
8.1. Examples of incremental, disruptive and radical innovations for the bioeconomy to 2030	239

List of figures

1.1. Current and expected integration across biotechnology applications	25
2.1. World land mass by expected population in 2030	35
2.2. Expected world primary energy demand (Mtoe)	39
3.1. USDA approved GM varieties as of May 2007, by trait.....	56
3.2. Approved GM crop plantings, 2007	58
3.3. Share of biopharmaceutical NMEs out of all pharmaceutical NMEs (three-year moving average), by year of first registration for market approval, 1989-2007.....	64
3.4. Number of diseases for which genetic testing is available as reported to GeneTests, by year	69
3.5. Number of GM field trials for trees and grasses for lignin modification and for all other traits.....	82
4.1. Observed (to 2005) and forecast (2006-15) GM share of global area cultivated, by crop	104
4.2. Number of biopharmaceutical NMEs expected to obtain marketing approval, by year	111
4.3. Number of identified gene-drug relationships, three-year moving average, by year of first publication	114
4.4. World ethanol and biodiesel production: projections to 2017	124
5.1. Percentage of all field trials by type of applicant for agronomic traits (three-year moving average).....	140
5.2. Public R&D expenditures for bioenergy and the share of total energy R&D in IEA countries	142
5.3. Doctoral degrees awarded in the physical, biological and agricultural sciences	143
5.4. Multiple futures for health regulation	151
6.1. Value-added market structure in biotechnology	165
6.2. Number of SMEs with one or more GM field trials in the OECD.....	168
6.3. Emerging business models in biotechnology	185

List of boxes

1.1. Demand for grains in 2030	21
1.2. The bioeconomy and sustainable development.....	22
1.3. Research spillovers	24
2.1. The global economic crisis	36
3.1. Ocean and marine applications	62
4.1. Predictive and preventive medicine	110
5.1. Biosecurity	145
5.2. Regulation and competitiveness: the <i>de facto</i> European moratorium on GM.....	149
5.3. Ethics and the bioeconomy	154

6.1. Mergers and acquisitions in the seed sector	167
6.2. Collaborative business models	172
6.3. Identification and validation of biomarkers	177
6.4. Life cycle analysis (LCA)	183
8.1. Types of innovations	237
8.2. Some policy approaches and tools for the emerging bioeconomy	240
8.3. Managing incremental biotechnologies for primary production	245
8.4. Managing disruptive and radical biotechnologies for primary production	246
8.5. Managing key uncertainties for primary production biotechnologies	248
8.6. Managing incremental biotechnologies for health	253
8.7. Managing disruptive and radical biotechnologies for health	255
8.8. Managing key uncertainties for health biotechnology	258
8.9. Managing incremental biotechnologies for industry	260
8.10. Managing disruptive and radical biotechnologies for industry	265
8.11. Managing key uncertainties for industrial biotechnology	266
8.12. Managing intellectual property for the bioeconomy	268
8.13. Managing knowledge spillovers and integration	269
8.14. Managing challenges at the global level	271